European Society of Medicine - Pathophysiological comparison and management of COVID-19 and influenza in Japan
By Dr. Masafumi Seki, Tohoku Medical and Pharmaceutical University, Sendai city, Japan
Abstract:
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
which causes coronavirus disease 2019 (COVID-19), has become a historic
pandemic, and dealing with it is one of the most important aspects of infectious
disease treatment today. SARS-CoV-2 has been found to have characteristic and
powerful infectivity (ability to propagate) and lethality (severity). With influenza,
primary influenza pneumonia from the virus itself is known to exist in addition to
secondary bacterial pneumonia. With COVID-19, on the other hand, it is
important to provide diagnosis and treatment while keeping acute respiratory
distress syndrome and pulmonary edema (alveolar flood) from a similar cytokine
storm, as well as severe angiopathy, in mind. The importance of complying with
hand hygiene and masks in infection control remains the same as in previous
general infection control measures and responses to influenza virus infections and
others, but recently, vaccination will likely be the key to infection control in
the community in Japan.
For more details please visit our website https://esmed.org/ and our YouTube channel below https://www.youtube.com/channel/UCp4b1lcWovYNFEKdvat-rQw/ and Twitter feed https://twitter.com/EuropeanSociet2
2021 European Society of Medicine General Assembly
Interesting info from past conferences located here
https://www.slideshare.net/MOsman14
Comments
Post a Comment